research use only
Cat.No.S7440
|
In vitro |
DMSO
: 8 mg/mL
(18.41 mM)
Water : Insoluble Ethanol : Insoluble The solubility data above are all experimental results (not literature values). |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
Read more about LEE011 (Ribociclib) solubility in DMSO or water
Read more about LEE011 (Ribociclib) working concentrations for cell culture treatment
LEE011 (Ribociclib) is a potent inhibitor of CDK4/cyclinD1 (2 nM), CDK4 (10 nM), Cyclin D1–CDK4 (10 nM), CDK6 (39 nM), CyclinD1/2/3–CDK6 (39 nM), CDK4/CDK6 (10/39 nM), cyclin D–CDK4/6 complexes (<40 nM), CDK2 (70 nM), CaMKII δ (153 nM), PDE4A (250 nM), PDE4C (4400 nM), PDE4B (4940 nM), PDE4D (>10000 nM), Cyclin A/E–CDK2 (76000 nM), Cyclin B–CDK1 (113000 nM), PDE4, CDK4/6. LEE011 (Ribociclib) exhibits the greatest inhibitory potency toward CDK4/cyclinD1 (IC50 = 2 nM).
| Information | LEE011 (Ribociclib) is an orally bioavailable, highly selective, ATP-competitive CDK4/6 inhibitor. It affects the CDK4/6-Rb signaling pathway. By binding to the ATP-binding pocket and blocking Rb phosphorylation, it induces G1 phase cell cycle arrest and effectively inhibits cancer cell proliferation. |
|---|---|
|
Read more about LEE011 (Ribociclib) IC50 for cell-based and cell-free assays |
|
| Primary Applications and Mechanism of Action | |
| Molecular Weight | 434.54 | Formula | C23H30N8O |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 1211441-98-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | LEE011 | Smiles | CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5 | ||
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.